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OBJECTIVES The objective of the present study was to elucidate the vasodilator mechanisms of nebivolol,
a high selective 1-receptor antagonist with antioxidant properties.
BACKGROUND Oxidative inactivation of nitric oxide (NO) is regarded as an important cause of its decreased
biological activity.
METHODS Oxidative stress was induced through the binding of oxidized (ox)-low-density lipoprotein
(LDL) to its specific endothelial receptor, called “lectin-like oxidized LDL receptor-1”
(LOX-1), in bovine and human endothelial cells and in Chinese hamster ovary cells stably
expressing bovine LOX-1 (BLOX-1-CHO cells). Reactive oxygen species (ROS), superoxide
(O2
 ), and NO were measured in cells by flow cytometry.
RESULTS Nebivolol and its 4-keto derivative prevented in a dose-dependent manner the increase of
ROS (p  0.001) and O2
 (p  0.001) in bovine aortic endothelial cells (BAECs), human
umbilical vein endothelial cells (HUVECs), and BLOX-1-CHO cells stimulated with
ox-LDL. Atenolol had no effect. The incubation of HUVECs and BAECs with ox-LDL
reduced basal and bradykinin-induced NO and nitrite concentration (p from 0.001 to
0.01). Nebivolol and its 4-keto derivative prevented the reduction of basal and stimulated
NO and nitrite concentration (p from 0.001 to 0.01) while atenolol had no effect. The
preincubation of BAECs with blocking anti-LOX-1 monoclonal antibody (LOX-1 mAb)
significantly counteracted the effect of ox-LDL on stimulated generation of NO (p 0.001),
but the effect was significantly lower than that of nebivolol and its 4-keto derivative alone (p
 0.01).
CONCLUSIONS In conclusion, the findings of the present study indicate that nebivolol increases NO also by
decreasing its oxidative inactivation. (J Am Coll Cardiol 2003;42:1838–44) © 2003 by the
American College of Cardiology Foundation
Endothelium plays an important role in the regulation of
vascular tone, the major endothelium-derived relaxing fac-
tor being nitric oxide (NO) (1,2). It is recognized that
essential hypertension is characterized by impaired
endothelium-dependent vasodilation (3), an abnormality
that is known to precede atherosclerosis and particularly
coronary artery disease (CAD) (4). This is especially rele-
vant because hypertension is a major risk factor for CAD.
The impairment of endothelium-dependent relaxation
has been linked to a decreased production and/or biological
activity of endothelium-derived NO (5).
Nebivolol, a highly selective 1-receptor antagonist with
antioxidant properties (6,7), has been shown to cause
vasodilation in animal models (8) and humans (9) and to
reverse endothelial dysfunction in essential hypertension
(10). It has been hypothesized that nebivolol induces vaso-
dilation through an endothelial 2-adrenergic receptor-
mediated NO production (11).
Because the vascular release of superoxide (O2
 ) is
increased in atherosclerotic arteries (12) and O2
 can
inactivate NO in a chemical reaction during which per-
oxynitrite is formed (13), oxidative inactivation of NO has
also been regarded as an important cause of endothelial
dysfunction in essential hypertension (14).
The present study was therefore performed to obtain
further insight into the mechanism underlying the effect of
nebivolol on NO production and, in particular, to explore
whether nebivolol reduces oxidative inactivation of NO and,
consequently, increases its intracellular availability in endo-
thelial cells exposed to oxidative stress.
METHODS
Cell cultures. Bovine aortic endothelial cells (BAECs) and
human umbilical vein endothelial cells (HUVECs) were
isolated and cultured as previously described (15,16). Chi-
nese hamster ovary-K1 (CHO-K1) cells and a CHO-K1
cell line stably expressing bovine lectin-like oxidized low-
density lipoprotein (LDL) receptor-1 (BLOX-1-CHO)
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(17) were cultured as previously described (15). Cell survival
was monitored according to the method of Landegren (18).
Addition and measurement of nebivolol in endothelial
cells. Nebivolol and its 4-keto and 4-OH derivatives (cour-
tesy of Menarini Ricerche, Firenze, Italy) and atenolol
(Sigma, St. Louis, Missouri) were dissolved in ethanol and
in M-199. Increasing amounts of the drugs (from 1 to 25
mol/l) were added to endothelial cell monolayers for 30
min at 37°C. Nebivolol was also incubated at different times
(30 to 180 min) with endothelial cells in order to ascertain
whether endothelial cells metabolize the drug. The deter-
mination of nebivolol and atenolol in cells was performed as
previously described (19,20).
Induction of oxidative stress in endothelial cells.
Oxidative stress in endothelial cells was induced by the
addition of oxidized (ox) LDL. The binding of ox-LDL to
the endothelial receptor called LOX-1 has already been
demonstrated to increase the intracellular concentration of
reactive oxygen species (ROS) (15) and O2
 (21).
LDL isolation and oxidation. Whole blood, containing
ethylenediamine tetraacetic acid (EDTA) (1 mg/ml), was
processed for LDL separation as previously described (15).
Cu2 modified LDL was prepared as reported (15), and the
extent of LDL oxidation was determined by thiobarbituric
acid-reactive substances (TBARS) (15). Protein was mea-
sured by the Pierce BCA protein assay reagent (22).
Translocation of cytosolic nicotinamide adenine dinucle-
otide phosphate oxidase components. The translocation
of p47phox and Rac1 was evaluated as previously described
(23). Briefly, HUVECs (5  107), incubated with 50 g
protein/ml of ox-LDL and native LDL (control) for 1 to 10
min at 37°C, were sonicated on ice in 0.5 ml relaxation
buffer (10 mM Pipes, pH 7.4, 100 mM KCl, 3 mM NaCl,
3.5 mM MgCl2, 1.25 mM EGTA, 10 g/ml leupeptin, 10
g/ml pepstatin, 10 g/ml aprotinin). Cytosol and mem-
branes were prepared by centrifugation on a discontinuous
gradient of 15% and 34% (w/w) sucrose at 120.000 g for 30
min at 4°C. The membrane pellets were transferred to a
nitrocellulose membrane and probed with the anti-p47phox
(Santa Cruz Biotechnology, Santa Cruz, California) or
anti-Rac1 antibody (Santa Cruz Biotechnology).
Before stimulation with ox-LDL, HUVECs were also
preincubated with anti-human LOX-1 monoclonal anti-
body (hLOX-1 mAb, 10 g/ml), p38 mitogen-activated
protein kinase (MAPK) inhibitor SB203580 (Calbiochem,
La Jolla, California) (10 mol/l), protein kinase C (PKC)
inhibitor bisindolylmaleimide (Calbiochem) (1 mol/l), and
increasing amounts of nebivolol (from 5 to 25 mol/l) for
30 min at 4°C.
ROS and O2
 measurement. Intracellular ROS and O2

levels were measured as described (15,21) by following the
oxidation of 2,7-dichlorofluorescein diacetate (DCFH-
DA) and hydroethidine (HE) by flow cytometry (Coulter
Corp., Hialeah, Florida). Cells were also tested for the
production of H2O2 (24) and extracellular O2
 (25) radi-
cals induced by ox-LDL.
For ROS, H2O2, and O2
 measurements, endothelial
cells were first preincubated with nebivolol or atenolol for 30
min at 37°C, then increasing concentrations (50 to 150 g
protein/ml) of ox-LDL and native LDL were incubated
with the cells for 10 min at 37°C in the presence of 5 mmol/l
arginine and 3 mol/l tetrahydrobiopterin (TB4). The
effect of 4-OH, and 4-keto derivatives of nebivolol on the
intracellular ROS and O2
 concentrations was also evalu-
ated under the previously specified experimental conditions.
To test the response specificity, nebivolol, its 4-keto
derivative, and anti-bovine LOX-1 monoclonal antibody
(bLOX-1 mAb) (30 g/ml) (17) were incubated with
BAECs, CHO-K1, and BLOX-1-CHO cells under the
previously specified experimental conditions.
Binding of labeled ox-LDL to BAECs and BLOX-1-
CHO cells and inhibition of binding. Oxidized LDL was
labeled using the fluorescent compound N, N-dipentadecyl-
aminostyrylpyridinium iodide (di-15-ASP) as described
previously (15). The data were fitted with GraFit (Erithacus
Software Ltd., Staines, United Kingdom). A 100-fold
excess of unlabeled ox-LDL, native LDL (100 g protein/
ml), bLOX-1 mAb (30 g/ml), polyinosinic acid (250
g/ml), and nebivolol (25 mol/l) were used as inhibitors.
NO measurement. Intracellular NO was measured in the
presence and absence of endothelial activation with brady-
kinin (100 nmol/l) (Sigma), as previously described, (21) by
utilizing the fluorescent indicator 4, 5 diaminofluorescein
diacetate (DAF-2 DA) in flow cytometry (Coulter Corp.).
Nitric oxide production was also monitored by following
levels of nitrite in the supernatant of stimulated HUVECs
and BAECs. Levels of nitrite were determined by a fluori-
metric assay (26). For NO measurement, HUVECs and
BAECs were first preincubated with nebivolol or atenolol
for 30 min at 37°C, then increasing concentrations (50 to
150 g protein/ml) of ox-LDL and native LDL were
Abbreviations and Acronyms
BAECs  bovine aortic endothelial cells
BLOX-1-CHO cells  CHO-K1 cells stably expressing
bovine LOX-1
bLOX-1 mAb  anti-bovine LOX-1 monoclonal
antibody
CAD  coronary artery disease
CHO-K1 cells  Chinese hamster ovary-K1 cells
eNOS  endothelial nitric oxide synthase
hLOX-1 mAb  anti-human LOX-1 monoclonal
antibody
HUVECs  human umbilical vein
endothelial cells
LDL  low-density lipoprotein
LOX-1  lectin-like ox-LDL receptor-1
MAPK  mitogen-activated protein kinase
NO  nitric oxide
O2
  superoxide
ox  oxidized
PKC  protein kinase C
ROS  reactive oxygen species
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incubated with endothelial cells for 10 min at 37°C in the
presence of bradykinin (100 nmol/l), 5 mmol/l arginine, and
3 mol/l TB4. The effect of 4-OH and 4-keto derivatives of
nebivolol on the intracellular basal and stimulated NO
concentration was also evaluated under the previously spec-
ified experimental conditions.
In order to ascertain whether the effect of ox-LDL on
intracellular NO concentration was dependent on O2
.-
produced by the binding of ox-LDL to LOX-1, bLOX-1
mAb (17) (30 g/ml) was used under the previously
specified experimental conditions.
Furthermore, to test the contribution of endothelial - or
-adrenergic receptors and 5-HT serotonergic receptors to
NO concentration after preincubation with nebivolol and
metabolites, a 2-adrenergic antagonist (butoxamine, 0.1
mmol/l; Sigma), an -adrenergic receptor blocker (phentol-
amine 10 mol/l; Sigma), or a 5-HT antagonist (NAN-
190; 1 mol/l; ICN, Frankurt/Main, Germany) was used.
Endothelial NO synthase activity measurement.
Endothelial NO synthase (eNOS) activity was measured by
evaluating the metabolism of 3H arginine to 3H citrulline as
described previously (21).
Statistical analysis. Statistical analysis was performed by
one-way analysis of variance with repeated measures fol-
lowed by post-hoc Tukey’s test for multiple comparisons
using the “SYSTAT” program and statistical software man-
ual (SYSTAT Inc., Evanston, Illinois) for Macintosh.
Statistical significance was inferred when p  0.05. All
reported p values were derived from Tukey’s test.
RESULTS
The addition of increasing amounts of nebivolol and ateno-
lol in HUVECs and BAECs determined a dose-dependent
intracellular increase of the drugs. The intracellular recovery
was higher for nebivolol than for atenolol (respectively
ranging from 65  6% to 70  8% for nebivolol and
metabolites and of 35  4% for atenolol (p  0.001). The
concentration of the nebivolol in endothelial cells was stable
for at least 3 h.
In our experimental conditions, the incubation of
HUVECs and BAECs with increasing amounts of ox-LDL
for 10 min at 37°C induced a sharp and dose-dependent
increase in intracellular concentration of ROS and O2
 (p
from 0.001 to 0.01, in experiments performed in trip-
licate on six different occasions for each concentration of
ox-LDL). Similarly, levels of H2O2 and O2
 in the
supernatant of both HUVECs and BAECs significantly
increased after the addition of ox-LDL (p from 0.001 to
0.01).
To determine whether the increase of ROS and O2

induced by ox-LDL was dependent on NADPH oxidase
activation and was, therefore, preceded by the translocation
of some cytosolic NADPH oxidase components, we isolated
membrane from ox-LDL-stimulated HUVECs and carried
out immunoblot analysis of p47phox and Rac1. The trans-
location of p47phox and Rac1 was first found at 1 min after
stimulation and peaked at 4 min (data not shown). We
found that incubation of ox-LDL with HUVECs deter-
mined a significant increase in both p47phox and Rac1
translocation. The translocation of p47phox and Rac1 was
inhibited by hLOX-1 mAb and respectively by bisindolyl-
maleimide and SB203580. Figure 1 shows representative
immunoblots of p47phox and Rac1 and the summarized
data obtained by densitometric analysis. Nebivolol and its
4-keto derivative dose-dependently reduced the intracellular
concentration of ROS and O2
 in HUVECs and BAECs
(p from 0.001 to 0.01). Atenolol and 4-OH derivative
of nebivolol had no effect. Figure 2A shows the effect of
nebivolol, its 4-keto derivative, and atenolol on O2
 -
induced by ox-LDL in HUVECs. The effect of nebivolol
on intracellular O2
 concentration was associated to a
reduced translocation of both p47phox and Rac1; the effect,
however, was much more evident for p47phox (Fig. 2B).
Nebivolol (25 mol/l) also reduced H2O2 from 4.52 
0.25 nmol/106 cells to 2.1  0.21 nmol/106 cells in
HUVECs (p 0.001) and from 4.92 0.44 nmol/106 cells
to 1.99 0.24 nmol/106 cells in BAECs (p 0.001); it also
decreased supernatant O2
 from 10.1  0.8 nmol/106 cells
Figure 1. Effect of native low-density lipoprotein (LDL), oxidized LDL
(ox-LDL), and ox-LDL plus anti-human LOX-1 monoclonal antibody
(hLOX-1 mAb), SB203580 and bisindolylmaleimide on the translocation
of p47phox and Rac1 to the plasma membrane of human umbilical vein
endothelial cells. The cells were preincubated with hLOX-1 mAb,
SB203580, and bisindolylmaleimide for 30 min at 37°C and then stimu-
lated with native LDL (control) and ox-LDL (50 g protein/ml) for 5 min
at 37°C. The figure shows representative blots of six different experiments
and the average data obtained by densitometric analysis. Results (means 
SD) are expressed as density in arbitrary units (AU). *p  0.001 versus
control; ¶p 0.001 versus ox-LDL; †p 0.05 versus ox-LDL. Solid bars
 p47phox; open bars  Rac1.
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to 4.6  0.5 nmol/106 cells in HUVECs (p  0.001) and
from 9.6  0.9 nmol/106 cells to 4.2  0.5 nmol/106 cells
in BAECs (p  0.001). Atenolol had no effect. All the
experiments regarding H2O2 and O2
 in the supernatant
were performed in triplicate on six different occasions.
To test the response specificity of nebivolol and its 4-keto
derivative, a fixed amount of ox-LDL (50 g protein/ml)
was incubated with BAECs, CHO-K1, and BLOX-1-
CHO cells for 10 min at 37°C after preincubation with
bLOX-1 mAb, nebivolol, and its 4-keto derivative for 30
min at 37°C. As shown in Figure 3, the O2
 concentration
was markedly reduced in BAECs and BLOX-1-CHO cells
preincubated with bLOX-1 mAb (p  0.001), nebivolol (p
 0.001), and its 4-keto derivative (p  0.001).
To exclude an interference of nebivolol on ox-LDL
binding to LOX-1, binding tests with labeled ox-LDL were
performed in BAECs and BLOX-1-CHO cells. The dose-
response relationship in di-15-ASP-labeled ox-LDL bind-
ing to BAECs and BLOX-1-CHO cells showed saturation
kinetics, and a 100-fold excess of unlabeled ox-LDL com-
pletely inhibited di-15-ASP-labeled ox-LDL binding to
BAECs and BLOX-1-CHO cells (data not shown). Scat-
chard analysis revealed that di-15-ASP-labeled ox-LDL
can bind to BAECs and BLOX-1-CHO cells with a
constant dissociation ranging from 31 to 37 g/ml. Oxi-
dized LDL, bLOX-1 mAb, and polyinosinic acid signifi-
cantly reduced the binding of di-15-ASP-labeled ox-LDL
both in BAECs and BLOX-1-CHO cells (p from 0.001
to 0.01). Nebivolol, its 4-keto derivative, and native LDL
had no effect.
The incubation of HUVECs and BAECs with ox-LDL
for 10 min in presence of DAF-2 DA, dose-dependently
reduced basal and bradykinin-induced intracellular NO
concentration (p from 0.001 to 0.01, n  12 for each
concentration of ox-LDL). Nebivolol and its 4-keto deriv-
ative prevented the reduction of basal and stimulated intra-
cellular NO induced by a fixed dose of ox-LDL (50 g
protein/ml) in HUVECs and BAECs (p from 0.001 to
0.01) while atenolol did not. Figure 4 shows the effect of
nebivolol, its 4-keto derivative, and atenolol on the reduc-
tion of basal and stimulated intracellular NO concentration
induced by ox-LDL in BAECs. Butoxamine, a 2-
Figure 2. (A) effect of increasing amounts of nebivolol, its 4-keto deriva-
tive, and atenolol on intracellular concentration of superoxide (O2
 )
induced by oxidized low-density lipoprotein (ox-LDL) in bovine aortic
endothelial cells. The cells were stimulated with ox-LDL (50 g protein/
ml) for 10 min at 37°C. Results are expressed as mean fluorescence
intensity (MFI) and are means  SD of experiments performed in
triplicate in six separate occasions. *p 0.001 versus control. Open bars 
nebivolol; solid bars  4-keto derivative; striped bars  atenolol. (B)
Effect of increasing amounts of nebivolol on the translocation of p47phox
and Rac1 to the plasma membrane of human umbilical vein endothelial
cells. The cells were preincubated with increasing amounts of nebivolol for
30 min at 37°C and then stimulated with ox-LDL (50 g protein/ml) for
10 min at 37°C. The figure shows representative blots of six different
experiments and the average data obtained by densitometric analysis.
Results (means  SD) are expressed as density in arbitrary units (AU). *p
 0.001 versus control. Solid bars  p47phox; open bars  Rac1.
Figure 3. Effect of nebivolol, its 4-keto derivative, and anti-bovine LOX-1
monoclonal antibody (bLOX-1 mAb) on oxidized low-density lipoprotein
(ox-LDL)-induced variation of superoxide (O2
 ) in bovine aortic endo-
thelial cells (BAECs), in Chinese hamster ovary-K1 (CHO) cells, and
CHO-K1 cell line stably expressing bovine LOX-1 (BLOX-1-CHO).
Nebivolol (25 mol/l), its 4-keto derivative (25 mol/l), and bLOX-1
mAb (30 g/ml) were preincubated with cells for 30 min at 37°C. The cells
were then stimulated with ox-LDL (50 g protein/ml) for 10 min at 37°C.
Results are expressed as mean fluorescence intensity (MFI) and are means
 SD of experiments performed in triplicate in six separate occasions. *p
0.001 versus ox-LDL.
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adrenergic antagonist; phentolamine, an -adrenergic re-
ceptor blocker; and NAN 190, a 5-HT receptor antagonist
had no effect on the counteracting effect of nebivolol.
Similarly, levels of nitrite in the supernatant of
bradykinin-stimulated endothelial cells dropped from 635
 25 pmol/well to 211 12 pmol/well (p 0.001, n 12)
in HUVECs and from 696  45 pmol/well to 186  18
pmol/well in BAECs (p 0.001, n 12) after the addition
of 50 g protein/ml of ox-LDL. The decrease was pre-
vented by nebivolol (25 mol/l) (respectively from 642 32
pmol/well to 612  38 pmol/well in HUVECs, and from
711 54 pmol/well to 677 44 pmol/well in BAECs, p
not significant, n  12) but not by atenolol at the same
concentration.
To test if the restoring action of nebivolol on the reduction
of intracellular NO concentration induced by ox-LDL was due
only to its effect on O2
 , we preincubated BAECs with
bLOX-1 mAb and measured bradykinin-stimulated intracel-
lular NO after induction of oxidative stress with ox-LDL.
Figure 5 shows that the preincubation of BAECs with
bLOX-1 mAb significantly counteracted the effect of ox-LDL
on bradykinin-stimulated generation of NO (p  0.001).
The counteracting effect of bLOX-1 mAb on intracellular
NO was significantly lower than that induced by nebivolol
and its 4-keto derivative alone (p  0.01) or nebivolol or its
4-keto derivative plus bLOX-1 mAb (p  0.001).
The results of this study also show that the eNOS activity
of BAECs significantly increased by a 5-min contact with
25 mol/l nebivolol; this effect was almost identical to that
induced by 100 nmol/l bradykinin (Fig. 6). Atenolol and
ox-LDL had no effect on eNOS activity.
DISCUSSION
The results of this study show that nebivolol and its 4-keto
derivative reduce the concentration of ROS and, in partic-
ular, of O2
 induced by ox-LDL in endothelial cells. The
increase in ROS and O2
 was previously shown to be
specifically related to the binding of ox-LDL to LOX-1 and
to be almost totally prevented by radical scavengers and by
bLOX-1 mAb (15,21). The fact that in this study nebivolol
and its 4-keto derivative work not only in endothelial cells,
but also in BLOX-1-CHO cells suggests that the effect of
the two compounds is specific for the ROS produced by the
binding of ox-LDL to LOX-1. This, of course, does not
mean that LOX-1 is the only receptor involved in nebivolol-
dependent effect because any other receptor producing ROS
or O2
 after stimulation (27,28) could be a potential target
of nebivolol activity. Nebivolol has already been demon-
strated to possess antioxidant activity (6,7). The effect of
nebivolol and, above all, of its 4-keto derivative we found in
this study may, therefore, be related to their radical scav-
enging activity. The possibility that nebivolol can affect the
binding of ox-LDL to LOX-1 is excluded by the binding
tests with labeled ox-LDL.
Furthermore, it has been previously hypothesized that
endothelial NADPH oxidase may be the source of the free
Figure 4. Effect of nebivolol, its 4-keto derivative, and atenolol on oxidized
low-density lipoprotein (ox-LDL)-induced variations of nitric oxide (NO)
in basal and bradykinin-stimulated bovine aortic endothelial cells. The cells
were then stimulated with ox-LDL (50 g protein/ml) for 10 min at 37°C.
Results are expressed as mean fluorescence intensity (MFI) and are means
 SD of experiments performed in triplicate in six separate occasions. *p
0.001 versus control.
Figure 5. Effect of bovine anti-LOX-1 monoclonal antibody (bLOX-1
mAb), nebivolol, and its 4-keto derivative alone or in combination with
bLOX-1 mAb on oxidized low-density lipoprotein (ox-LDL)-induced
variations of nitric oxide (NO) in bradykinin-stimulated bovine aortic
endothelial cells (BAECs). Nebivolol (25 mol/l), its 4-keto derivative (25
mol/l), and bLOX-1 mAb (30 g/ml) were preincubated with BAECs
for 30 min at 37°C. The cells were then stimulated with ox-LDL (50 g
protein/ml) for 10 min at 37°C. Results are expressed as mean fluorescence
intensity (MFI) and are means  SD of experiments performed in
triplicate on six separate occasions. *p  0.001 versus control; †p  0.001
versus ox-LDL; ¶p  0.01 versus bLOX-1 mAb.
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radicals generated by activated LOX-1 (21,29). NADPH
oxidase is a multicomponent enzyme consisting of at least
two membrane components (gp91phox and p22phox) and
three cytosolic proteins (p47phox, p67phox, and Rac) (30).
All the classic NADPH subunits, including p47phox and
Rac1 have already been shown to be expressed in human
endothelial cells and in particular in HUVECs (31). In
resting cells the oxidase is dormant and its components
separately exist between the membrane and the cytosol (30).
When cells are exposed to appropriate stimuli, NADPH
oxidase is activated by association of these components on
the plasma membrane (30). Actually, neutrophil and endo-
thelial NADPH oxidase exhibit differences in their activity.
In fact, a substantial proportion of NADPH oxidase in
unstimulated endothelial cells, in contrast to the neutrophil
enzyme, exists as a preassembled intracellular complex
associated with the cytoskeleton (31). Nevertheless, a sig-
nificant translocation of p47phox to the plasma membrane
was demonstrated under stimulation with angiotensin II
(32), consistent with the oxidase being present in the
membrane fraction. Taken together, these findings support
the conclusion of our study that the translocation of
p47phox and Rac1 really occurred in our experimental
conditions and that endothelial NADPH oxidase may be
the source of the free radicals generated by activated
LOX-1. The fact that the translocation of p47phox and
Rac1 was greatly reduced, respectively, by bisindolylmalei-
meide and SB203580 may indicate that p38 MAPK is more
responsible for the translocation of Rac and PKC for the
translocation of p47phox. In this context, it is of interest
that these two kinases have already been shown to be
associated with LOX-1 activation (33,34). Because in this
study the translocation of Rac1 and in particular of p47phox
was reduced by nebivolol, a conclusion can be drawn that
this compound and its 4-keto derivative may reduce ROS
production also by affecting the signaling pathways leading
to NADPH oxidase activation.
Previous findings by our group have shown that the
binding of ox-LDL (21) and platelets (29) to LOX-1
reduces the intracellular and extracellular concentration of
NO in endothelial cells through an increased cellular pro-
duction of O2
 . In the present study, we demonstrated that
nebivolol and its 4-keto derivative prevented the reduction
of basal and bradykinin-stimulated NO induced by ox-LDL
in BAECs. Because the reduction of NO was counteracted
by bLOX-1 mAb, another conclusion of this study is that
the effect of nebivolol can be at least partially explained by
its effect on O2
 , which can inactivate NO in a chemical
reaction during which peroxynitrite is formed (13). From
our results it is, however, clear that the effect of nebivolol
and its 4-keto derivative on NO cannot be explained only by
their effect on O2
 because the counteracting effect of
bLOX-1 mAb was significantly lower than that caused by
nebivolol and its 4-keto derivative alone or in combination
with the LOX-1 blocking antibody. Taken together, these
results suggest that nebivolol and its 4-keto-derivative may
increase NO in endothelial cells by working in at least two
different ways: they reduce O2
 concentration and conse-
quently peroxynitrite formation and increase NO produc-
tion. The conclusion on the effect of nebivolol on NO
production is supported by the results we obtained by
measuring eNOS activity in endothelial cells. The activity of
the enzyme was more than doubled by a 5-min contact with
nebivolol; this effect was identical with that induced by
bradykinin. It is noteworthy that atenolol and ox-LDL were
devoid of any effect on eNOS activity. Our results on NO
production are in agreement with a series of previous studies
showing that the mechanism of vasodilator action of
nebivolol is attributed to activation of eNOS in vascular
endothelial cells (9,11,35).
The results of this study and, in particular, the inhibitory
effect of nebivolol on O2
 concentration may have impli-
cations in vivo. In fact, oxidative inactivation of NO has
been regarded as an important cause of endothelial dysfunc-
tion in essential hypertension (14). Furthermore, it has been
recognized for a long time that atherosclerotic blood vessels
are very susceptible to the development of vasospasm in vivo
(36), and the current weight of evidence suggests that
impaired endothelium-dependent vasodilation plays a cen-
tral role in the mechanisms leading to ischemic manifesta-
tions (37). In this context, it has been demonstrated that
peroxynitrite, generated by a rapid combination of NO and
O2
 (13), inactivates prostacyclin (PGI2) synthase via
chemical nitration, leaving PGH2 unmetabolized, which
then causes vasospasm and platelet aggregation (38). By
reducing O2
 , nebivolol may reduce peroxynitrite and,
therefore, reduce vasospasm and platelet aggregation. Fi-
nally, ROS have been shown to induce activation of nuclear
Figure 6. Effect of oxidized low-density lipoprotein (ox-LDL), nitro-L-,
and D-arginine methyl ester hydrochloride (L- and D-NAME), bradyki-
nin, nebivolol, and atenolol on endothelial nitric oxide synthase (eNOS)
activity in bovine aortic endothelial cells (BAECs). Ox-LDL (50 g
protein/ml), L- and D-NAME (2 mmol/l), bradykinin (100 nmol/l),
nebivolol (25 mol/l), and atenolol (25 mol/l) were preincubated with
BAECs for 5 min at 37°C. Results are expressed as pmol citrulline/mg
protein/min and are means  SD of experiments performed in triplicate in
six separate occasions. *p  0.001 versus control.
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factor-kB (15), a transcription factor involved in the first
steps of atherosclerotic plaque formation (39) and to play a
pivotal role in regulating apoptosis (40). Nebivolol, there-
fore, besides reducing blood pressure, may help prevent
atherosclerotic initiation and complications.
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